Birdwatch Note
2024-10-03 14:16:46 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
初歩的な誤情報である 現在mRNAワクチンは特例承認でなく通常承認である https://www.modernatx.com/ja-JP/press-release/2024/20240329 https://www.pfizer.co.jp/pfizer/company/press/2024/2024-05-17 また,特例承認でも治験プロセス等は省略されていない https://www.mhlw.go.jp/content/11121000/001036029.pdf 有効性は限定的でなくむしろ優秀 死亡予防率90% https://pubmed.ncbi.nlm.nih.gov/35475889/ 症候性感染予防効果 追加接種後90日以内: 58.5% 91-180日: 41.1% 追加接種後90日以内重症化予防効果: 77.3% https://pubmed.ncbi.nlm.nih.gov/38288980/ 副反応も他ワクチンと比較し同等か少ない 心筋炎 新型コロナvax: 18.2/100万回接種 その他: 56.0/100万回 https://pubmed.ncbi.nlm.nih.gov/25793705/ 素人のデマでなく コロナ診療する医師,原著論文のある専門家,公的機関の情報を参照しましょう
Written by DBED9C596CB186E1859671BECC978DBA27B4A23F89BF9D7FC47BE876C4028F03
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1841780268329480371
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1841844850788073626
- noteId - 1841844850788073626
- participantId -
- noteAuthorParticipantId - DBED9C596CB186E1859671BECC978DBA27B4A23F89BF9D7FC47BE876C4028F03 Participant Details
- createdAtMillis - 1727965006905
- tweetId - 1841780268329480371
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 0
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 1
- misleadingMissingImportantContext - 1
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- 初歩的な誤情報である 現在mRNAワクチンは特例承認でなく通常承認である https://www.modernatx.com/ja-JP/press-release/2024/20240329 https://www.pfizer.co.jp/pfizer/company/press/2024/2024-05-17 また,特例承認でも治験プロセス等は省略されていない https://www.mhlw.go.jp/content/11121000/001036029.pdf 有効性は限定的でなくむしろ優秀 死亡予防率90% https://pubmed.ncbi.nlm.nih.gov/35475889/ 症候性感染予防効果 追加接種後90日以内: 58.5% 91-180日: 41.1% 追加接種後90日以内重症化予防効果: 77.3% https://pubmed.ncbi.nlm.nih.gov/38288980/ 副反応も他ワクチンと比較し同等か少ない 心筋炎 新型コロナvax: 18.2/100万回接種 その他: 56.0/100万回 https://pubmed.ncbi.nlm.nih.gov/25793705/ 素人のデマでなく コロナ診療する医師,原著論文のある専門家,公的機関の情報を参照しましょう
Note Ratings
rated at | rated by | |
2024-10-04 06:01:47 -0500 | Rating Details | |
2024-10-03 23:27:20 -0500 | Rating Details | |
2024-10-03 22:55:22 -0500 | Rating Details | |
2024-10-03 22:48:40 -0500 | Rating Details | |
2024-10-03 22:33:39 -0500 | Rating Details | |
2024-10-03 22:09:51 -0500 | Rating Details | |
2024-10-03 22:09:45 -0500 | Rating Details | |
2024-10-03 22:05:06 -0500 | Rating Details | |
2024-10-03 21:25:55 -0500 | Rating Details | |
2024-10-03 21:16:21 -0500 | Rating Details | |
2024-10-03 21:14:39 -0500 | Rating Details | |
2024-10-03 19:14:37 -0500 | Rating Details | |
2024-10-03 19:03:59 -0500 | Rating Details | |
2024-10-03 19:02:00 -0500 | Rating Details | |
2024-10-03 18:53:49 -0500 | Rating Details | |
2024-10-03 18:49:11 -0500 | Rating Details | |
2024-10-03 18:46:59 -0500 | Rating Details | |
2024-10-03 18:04:06 -0500 | Rating Details | |
2024-10-03 18:02:17 -0500 | Rating Details | |
2024-10-03 18:00:25 -0500 | Rating Details | |
2024-10-03 17:28:58 -0500 | Rating Details | |
2024-10-03 17:24:16 -0500 | Rating Details | |
2024-10-03 17:13:37 -0500 | Rating Details | |
2024-10-03 17:06:31 -0500 | Rating Details | |
2024-10-03 16:50:51 -0500 | Rating Details | |
2024-10-03 16:31:43 -0500 | Rating Details | |
2024-10-03 16:19:23 -0500 | Rating Details | |
2024-10-03 16:16:59 -0500 | Rating Details | |
2024-10-03 16:10:56 -0500 | Rating Details | |
2024-10-03 16:03:53 -0500 | Rating Details | |
2024-10-03 15:55:37 -0500 | Rating Details | |
2024-10-03 15:31:37 -0500 | Rating Details | |
2024-10-03 15:14:23 -0500 | Rating Details | |
2024-10-03 15:11:16 -0500 | Rating Details | |
2024-10-03 15:10:19 -0500 | Rating Details | |
2024-10-03 14:49:59 -0500 | Rating Details | |
2024-10-03 13:55:45 -0500 | Rating Details | |
2024-10-03 13:39:46 -0500 | Rating Details | |
2024-10-03 12:30:15 -0500 | Rating Details | |
2024-10-03 12:22:18 -0500 | Rating Details | |
2024-10-03 12:05:31 -0500 | Rating Details | |
2024-10-03 11:59:04 -0500 | Rating Details | |
2024-10-03 11:48:12 -0500 | Rating Details | |
2024-10-03 11:16:02 -0500 | Rating Details | |
2024-10-03 10:59:33 -0500 | Rating Details | |
2024-10-03 10:37:30 -0500 | Rating Details | |
2024-10-03 10:29:59 -0500 | Rating Details | |
2024-10-03 10:23:08 -0500 | Rating Details | |
2024-10-03 10:16:15 -0500 | Rating Details | |
2024-10-03 10:10:57 -0500 | Rating Details | |
2024-10-03 10:10:33 -0500 | Rating Details | |
2024-10-03 10:09:24 -0500 | Rating Details | |
2024-10-03 10:07:24 -0500 | Rating Details | |
2024-10-03 10:03:38 -0500 | Rating Details | |
2024-10-03 10:03:26 -0500 | Rating Details | |
2024-10-03 10:03:15 -0500 | Rating Details | |
2024-10-03 09:58:00 -0500 | Rating Details | |
2024-10-03 09:56:26 -0500 | Rating Details | |
2024-10-03 09:56:09 -0500 | Rating Details | |
2024-10-03 09:53:14 -0500 | Rating Details | |
2024-10-03 09:50:02 -0500 | Rating Details | |
2024-10-03 09:49:43 -0500 | Rating Details | |
2024-10-03 09:42:10 -0500 | Rating Details | |
2024-10-03 09:41:55 -0500 | Rating Details | |
2024-10-03 09:33:22 -0500 | Rating Details | |
2024-10-03 09:31:53 -0500 | Rating Details | |
2024-10-03 09:29:13 -0500 | Rating Details | |
2024-10-03 09:24:42 -0500 | Rating Details | |
2024-10-06 00:47:23 -0500 | Rating Details | |
2024-10-03 21:51:33 -0500 | Rating Details | |
2024-10-03 20:40:18 -0500 | Rating Details | |
2024-10-03 16:44:27 -0500 | Rating Details | |
2024-10-03 15:34:39 -0500 | Rating Details | |
2024-10-03 13:12:36 -0500 | Rating Details | |
2024-10-03 12:33:09 -0500 | Rating Details | |
2024-10-03 11:09:25 -0500 | Rating Details | |
2024-10-03 10:13:34 -0500 | Rating Details | |
2024-10-09 15:12:56 -0500 | Rating Details | |
2024-10-03 22:10:44 -0500 | Rating Details | |
2024-10-03 19:33:33 -0500 | Rating Details | |
2024-10-03 18:43:32 -0500 | Rating Details | |
2024-10-03 15:23:26 -0500 | Rating Details | |
2024-10-03 11:43:07 -0500 | Rating Details | |
2024-10-03 09:30:31 -0500 | Rating Details | |
2024-10-07 05:24:15 -0500 | Rating Details | |
2024-10-05 06:21:36 -0500 | Rating Details | |
2024-10-03 19:33:30 -0500 | Rating Details | |
2024-10-03 17:28:33 -0500 | Rating Details | |
2024-10-03 17:16:59 -0500 | Rating Details | |
2024-10-03 16:37:56 -0500 | Rating Details | |
2024-10-03 15:06:06 -0500 | Rating Details | |
2024-10-03 10:51:35 -0500 | Rating Details | |
2024-10-03 10:29:38 -0500 | Rating Details | |
2024-10-03 10:14:18 -0500 | Rating Details | |
2024-10-03 10:07:41 -0500 | Rating Details | |
2024-10-03 09:47:11 -0500 | Rating Details | |
2024-10-03 09:29:09 -0500 | Rating Details |